Explore the Agenda
7:30 am Registration & Morning Coffee
Expanding Cell Therapy Impact in Europe through Smarter Investment Strategies, Innovative Science, & Patient-Centric Access Models
8:30 am Industry Leaders Fireside Chat: Navigating Europe’s Cell Therapy Landscape Amid Investment Pressures, Novel Approaches, & Opportunities for Patient Access
- Discuss how investment headwinds are shaping company strategies and what it takes to sustain progress in Europe
- Highlight the most promising scientific advances, including novel indications, armouring strategies, and in-vivo approaches
- Explore how patient access models, from point-of-care manufacturing to evolving reimbursement pathways, can unlock future growth
9:15 am Unlocking the Potential of 3rd Generation CARs with Dual Co-Stimulation
- Showcase the unique design of the only 3rd generation CAR with CD19 targeting plus CD28 and CD137 co-stimulatory domains
- Discuss clinical insights on safety and efficacy
New Data
9:45 am Evaluating Long-Term Outcomes of Approved CAR-T Therapies in Real- World Settings & Highlighting Upcoming CAR-T Therapies
- Share results from a multicentre Phase 2 trial in adult B-ALL, marking the first centralised EMA commercialisation request for a CAR-T product
- Compare real-world evidence of approved CAR-T and off-label B-cell lymphoma treatments to assess long-term efficacy and safety
- Discuss insights from Hospital Clinic Barcelona’s experience as one of Europe’s earliest CAR-T/TCR treatment centres
New Data
10:15 am A Landscape Overview of CAR & TCR Therapies
- Reviewing recent developments within the CAR and TCR deal landscape
- An overview of recent and potential CAR and TCR regulatory announcements
- Highlighting prevalent platform technologies, armoring strategies and novel in vivo CAR therapies
10:45 am Morning Break & Speed Networking
R&D Track
Innovation in Science
Highlighting CAR-NK & CAR-Treg Approaches as Versatile, Scalable & Safe Approaches
11:30 am Advancing Second-Generation Off-the-Shelf CAR-NK Therapies for Safer, More Scalable Cancer Treatment
- Explore how CAR-engineered NK cells enhance tumour targeting, persistence, and safety
- Discuss how these next-generation, allogeneic NK products improve manufacturability, cost efficiency, and clinical accessibility
New Data
12:00 pm T regulatory cells in the treatment of autoimmune diseases – therapy built on experience with patients
- Clinical trials with ex vivo manufactured polyclonal T regulatory cells (Tregs) led to first authorisations of this cellular therapy in GvHD and type 1 diabetes
- Thorough analysis of the immune system of the patients treated in trials led to novel generations of cellular therapies around Tregs now heading towards clinical phase
- Novel generations of Tregs can be prepared as autologous and allogeneic medicinal products, which facilitates scaling up of the manufacturing and delivery to all patients in the need of Tregs therapy
12:30 pm Advancing Next-Generation NK Platforms through Antibody-Guided CAR-like NK Cells
- Showcasing a CAR-like NK platform that achieves targeted cytotoxicity via monoclonal antibody attachment, eliminating the need for genetic modification
- Presenting preclinical data validating the platform’s potent CD16-mediated activity
New Data
Manufacturing Track
Realising Scale & Access
Track Chair:
Enhancing Cell Therapy Production with Advanced Platforms & Automation
11:30 am Scaling Manufacturing of CAR-Neutrophils to Enhance Persistence & Overcome Exhaustion
- Explore scalable processes for producing CAR-engineered neutrophils with consistent quality and functionality
- Discuss how optimised culture and differentiation conditions prevent exhaustion and extend therapeutic lifespan
- Highlight how CAR-neutrophil manufacturing can enable durable, off-the-shelf solutions for solid tumour treatment
12:00 pm Session Reserved for Minaris
12:30 pm Exploring Automation to Scale Out Autologous CAR-T Manufacturing
- Examine how automation enables scalable, parallelised production of autologous CAR-T therapies without compromising quality
- Discuss how streamlined, modular manufacturing platforms can lower costs and accelerate patient access
1:00 pm Lunch & Networking Break
2:00 pm Uncovering the Potential of CD19 CAR-Tregs: Pre- Clinical Data Driving the Next Wave of Treg Therapies
- Evaluate CD19 CAR-Treg design, function, and in preliminary data
- Understand how pre-clinical results inform translational and clinical readiness
Developing Cutting Edge Tools to Discover Novel Targets & Receptor Constructs to Broaden Therapeutic Reach
2:30 pm Session Reserved for Nona Bio
2:40 pm Panel Discussion: Leveraging AI & Machine Learning to Accelerate R&D & Construct Design
- Explore how AI-driven tools are being applied to design next- generation receptor constructs with improved precision and functionality
- Discuss the use of machine learning in identifying novel targets and accelerating preclinical discovery
- Highlight the challenges of obtaining sufficient, high-quality datasets
Enabling Local Manufacturing to Accelerate Patient Access & Streamline CGT Site Operations
2:00 pm Fully automated CGT Manufacturing: A Real-World Example of Fast, Reliable, and Affordable Production
- Automation of manufacturing and quality control processes result in higher reliability and ensure consistent quality
- Digitalization and device implementation improve documentation and release processes to enable faster vein to vein times
- Automation significantly reduces the effort required for operator training and qualification.
- Closed manufacturing and final filling processes enable downgrading of manufacturing environment
2:30 pm Panel Discussion: Feasibility & Merits of Setting up Point of Care Manufacturing to Drive Patient Access & Reduce CGT Costs
- Evaluating the true feasibility and practicality of point-of-care manufacturing in today’s CGT landscape
- Weigh upfront costs, staffing, and infrastructure requirements against potential long-term savings
- Discussing whether the benefits of local access outweigh regulatory, operational, and scalability hurdles
3:00 pm Academic Case Study: Key Steps to Achieve a GMPGrade Cell Therapy Facility
- Lessons learned from overcoming resource constraints, timelines, and regulatory inspections in an academic environment
- Planning and designing an academic GMP facility with the right infrastructure, cleanroom classifications, and compliance standards
3:30 pm Reserved for InvIOs
3:40 pm Afternoon Break & Poster Session
Clinical Data Showcase: Demonstrating Breakthroughs with Clinical Data to Validate Innovation
4:25 pm Advancing CAR-T Therapies with Real-World Clinical Data to Drive Next- Generation Development
- Share up-to-date clinical data from the ongoing CAR-T program in T-cell leukaemia
- Discuss the latest development from OneChain’s next-generation CAR-T products across hematologic malignancies and solid tumours
- Explore advantages and opportunities with OneChain’s allogeneic iPSC-derived gamma delta T-cell platform
New Data
4:55 pm Overcoming Barriers to Homegrown CAR-TCR Development in Low & Middle Income Countries (LMICs)
- Examine key challenges in developing CAR-TCR therapies from bench to bedside in low- and middle-income countries, from infrastructure to funding gaps
- Share practical solutions to reduce costs, strengthen local manufacturing capacity, and accelerate clinical translation
- Present clinical data showcasing progress and potential for scalable, sustainable innovation in LMIC settings
5:25 pm Use of Quantum Engine to Develop Multiplex Dual-Targeting CD19/CD20 CAR-T (SCM) Therapy for B-Cell Malignancies
- Introduce Quantum Engine for non-viral gene therapy
- Describe the benefits of dual-targeting CD19/CD20 T(SCM) cells to overcome antigen escape and improve response durability
- Present preliminary findings from a Phase I open-label trial of GF-CART01 for relapsed or refractory B-cell haematologic cancers
New Data